Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Axumin PET/CT for Risk Stratification in Localized Prostate Cancer
NCT03373006Phase 2Completed
- Sponsor
- HALO Diagnostics
- Start
- Feb 2018
- Primary completion
- Jan 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of fluciclovine f 18 in prostate cancer (PCa), sponsored by HALO Diagnostics. Started Feb 2018; status: completed.
02
Drugs
fluciclovine f 18
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT03373006.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03373006.